FDA Inspection
Novocol Pharmaceutical of Canada, Inc.Novocol Pharmaceutical of Canada, Inc. – FDA Inspection, Jun 18, 2019
Record Details
This FDA Inspection record concerns Novocol Pharmaceutical of Canada, Inc., with an inspection on June 18, 2019, issued by the Center for Drug Evaluation and Research, covering drugs.
- Person
View Company Profile
ID · 5a9546ca-45e2-4264-a4d2-5e3257507745
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1093310
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
FDA Citations
1- 21 CFR 211.113(b)Procedures for sterile drug products
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Novocol Pharmaceutical of Canada, Inc.
10| Date | Classification | Office | Project area |
|---|---|---|---|
| May 3, 2024 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| January 30, 2020 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| June 21, 2019 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| November 2, 2018 | Not classified | Office of Inspections and Investigations | |
| July 26, 2017 | VAI | Center for Drug Evaluation and Research | Postmarket Surv. and Epidemiology |
Other documents for Novocol Pharmaceutical of Canada, Inc.
- FDA Inspection 1243223 - 2024-05-03
- FDA Inspection 1117454 - 2020-01-30
- FDA Inspection 1098218 - 2019-06-21
- FDA Inspection 1072908 - 2018-11-02
- FDA Inspection 1019963 - 2017-07-26
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.